Killing of chronic lymphocytic leukemia by the combination of fludarabine and oxaliplatin is dependent on the activity of XPF endonuclease

PURPOSE: Chronic lymphocytic leukemia (CLL) resistant to fludarabine-containing treatments responds to oxaliplatin-based therapy that contains fludarabine. We postulate that a mechanism for this activity is the incorporation of fludarabine into DNA during nucleotide excision repair (NER) stimulated...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Cancer Res
Hlavní autoři: Zecevic, Alma, Sampath, Deepa, Ewald, Brett, Chen, Rong, Wierda, William, Plunkett, William
Médium: Artigo
Jazyk:Inglês
Vydáno: 2011
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5534342/
https://ncbi.nlm.nih.gov/pubmed/21632856
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-10-2561
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky